Publications
Edgeworth experts publish in a variety of scholarly and trade journals on a range of topics including economics, legal cases, and data analytics. Discover our most recent thoughts and findings here.
- Published Article, Law360 | 07.28.2025
Enacted on July 4, the One Big Beautiful Bill Act, or H.R. 1, includes a provision for "no tax on overtime." As a result, salaried employees who work long hours but do not receive overtime compensation could benefit from a change in their Fair Labor Standards Act status.
- Published Article, GCR Data & Antitrust Guide | 06.04.2025
This article discusses the specific data-focused theories of harm presented by the agencies and how economic analysis was used to assess these theories of harm in United States of America, et al. v. UnitedHealth Group.
- Published Article, ABA Antitrust Section M&A Committee Newsletter | 03.11.2025
On February 13, 2025, the Antitrust Law Section hosted a webinar with Judge William Young of the U.S. District Court for the District of Massachusetts. The webinar, titled Process Lessons in DOJ v JetBlue Spirit, was moderated by Dr. Craig Malam, Partner at Edgeworth Economics, and Clotilde Le Roy, Associate at Cleary Gottlieb Steen & Hamilton LLP.
- Published Article, Law360 | 03.07.2025
This article will examine how the rule changes are to affect agency economists' analysis during the initial waiting period and the effect on how the agencies target or identify from among all notified transactions those that warrant in-depth reviews.
- Our Curious Amalgam | 03.03.2025
Private class action lawsuits play a significant role in the vindication and development of U.S. antitrust law. But what are attorneys and courts to do when they know there's an injured class, but are not quite sure who's in it and who's not?
- Published Article, ABA Antitrust Source | 02.28.2025
In this article, we trace the evolution of economic theories in “algorithmic collusion” litigation and describe a framework for the antitrust injury and damages issues that will be relevant as these cases proceed.
- Published Article, Journal of Direct Selling Research | 01.24.2025
On April 30, 2024, the FTC published updated Business Guidance Concerning Multi-Level Marketing that details the current principles and practices that the FTC considers in its assessment of whether an MLM is offering an unlawful compensation structure and operating as a pyramid scheme.
- Law360 | 12.10.2024
In the November election, California voters narrowly rejected Proposition 32, which would have increased the state's minimum wage.
- CPI Antitrust Chronicle | 12.02.2024
This article explores the economic dynamics and competition issues within the fast-advancing Generative Artificial Intelligence (AI) industry. Generative AI, encompassing hardware, models, and applications, has seen rapid growth across sectors, offering potential for efficiency gains and innovation.
- ABA Antitrust Law Section’s Economics Committee | 11.14.2024
“Dark patterns” is a term used to describe potentially deceptive app or website designs that could manipulate consumers to make choices they would otherwise not make.
- Published Article, Competition Journal of the Antitrust and Unfair Competition Law Section of the California Lawyers Association | 10.23.2024
In class action litigation, a court’s decision as to whether a particular class should be certified turns, in part, on the question of predominance. In antitrust class actions in particular, the predominance assessment relies heavily on economic analysis.
- Published Article, Bloomberg Law | 09.18.2024
Pharmaceutical manufacturers introduce new and improved versions of drugs as part of their research and development strategy. However, concerns about antitrust violations are raised when manufacturers are alleged to use anticompetitive tactics to stifle generic competition.
- Published Article, Bloomberg Law | 08.21.2024
In the last year, the Federal Trade Commission (FTC) has taken several actions to challenge patents listed in the Food and Drug Administration's (FDA) Orange Book.
- Published Article, Law360 | 08.13.2024
On June 6, a motion for summary judgment was granted in In re: Lipitor Antitrust Litigation, dismissing claims of a pay-for-delay settlement from Pfizer Inc., the manufacturer of Lipitor, to Ranbaxy.
- Published Article, Law360 | 08.09.2024
On April 30, the FTC published updated business guidance concerning multilevel marketers, or MLMs. This 2024 guidance details the current principles and practices that the FTC claims to consider in its assessment of whether an MLM is offering an unlawful compensation structure and operating as a pyramid scheme.